Tag: regulatory compliance

DENVER, June 14, 2025 (GLOBE NEWSWIRE) -- Amid the trend of mainstream financial institutions restructuring their human resources systems, Zinemx Exchange has drawn on industry experience to complete a team restructuring and further optimize its operational management system, accelerating its expansion into international markets. David Reynolds, Founder and CEO of Zinemx, emphasized that an efficient team and a compliant management system are essential, and that the new operational structure will provide strong support for the international development of the platform.

HONG KONG, June 14, 2025 (GLOBE NEWSWIRE) -- GA (Int’l) Capital Management Limited confirms that the Securities and Futures Commission (SFC) of Hong Kong issued a temporary restriction notice on June 6 2025, pursuant to Sections 204 and 205 of the Securities and Futures Ordinance (SFO). This action follows an incident involving a mainland China-registered corporate client who submitted fraudulent tax documentation during compliance onboarding.

Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips. 

Toronto, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- In a significant step toward mainstreaming crypto-based passive income, Coinchange and Kanga Exchange have joined forces to offer automated yield solutions—resulting in over 30% user adoption in just months. The partnership between Coinchange, a digital asset management platform, and Kanga Exchange, a leading cryptocurrency exchange platform, demonstrates how the integration of yield-generating solutions can simplify access to passive income opportunities. The collaboration has enabled over 30% of Kanga’s active users to generate passive income through multi-strategy active portfolio management solutions on their digital asset holdings without requiring active supervision or technical expertise.

Driven by Stable Legacy Sales and Ongoing Cost Savings Initiatives

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.